William Acheampong
Family · Columbus, OHNPI 1982120564
Payments from drug & device makers
Across 307 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$628
- Otsuka America Pharmaceutical, Inc.$615
- Pfizer$338
- GSK$254
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$194
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,594100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 118 | $1,558 |
| AstraZeneca | 33 | $628 |
| Otsuka America Pharmaceutical, Inc. | 38 | $615 |
| Pfizer | 26 | $338 |
| GSK | 17 | $254 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $194 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $161 |
| Lucid Diagnostics Inc. | 12 | $142 |
| Amphastar Pharmaceuticals, Inc. | 5 | $102 |
| Lilly USA, LLC | 5 | $75 |
| Astellas Pharma US Inc | 4 | $56 |
| Dexcom, Inc. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 3 | $46 |
| Lundbeck LLC | 2 | $43 |
| Amgen(2 entities) | 3 | $43 |
| Novartis | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Mylan Specialty L.p. | 2 | $36 |
| Merck | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $36 |
| Novo Nordisk | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,594 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 126 | $81,972 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $40,389 |
| MounjaroTirzepatide | 25 | $25,644 |
| EliquisApixaban | 44 | $24,696 |
| TrulicityDulaglutide | 23 | $21,501 |
| RybelsusSemaglutide | 22 | $20,184 |
| JardianceEmpagliflozin | 34 | $19,594 |
| JanuviaSitagliptin Phosphate | 28 | $18,504 |
| FarxigaDapagliflozin Propanediol | 31 | $17,202 |
| VascepaIcosapent Ethyl | 30 | $10,651 |
| LinzessLinaclotide | 15 | $7,956 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 198 | $5,965 |
| TradjentaLinagliptin | 11 | $5,522 |
| Ventolin HfaAlbuterol Sulfate | 94 | $4,858 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $4,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $254 | $81,972126 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $628 | $57,59196 claims |
| Lilly USA, LLCMounjaro, Trulicity | $75 | $47,14548 claims |
| PfizerEliquis | $338 | $24,69644 claims |
| Novo NordiskRybelsus | $25 | $20,18422 claims |
| MerckJanuvia | $36 | $18,50428 claims |
| AbbVieLinzess | $1,558 | $7,95615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Columbus
- Christina GastColumbus$66K
- Beth LoessinColumbus$34K
- Mary HurleyColumbus$15K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.